Core Viewpoint - SciSparc Ltd. has signed a binding term sheet to acquire a portfolio of patents, trademarks, and intellectual property rights related to innovative endoscopic systems, including the MUSE™ system, from Xylo Technologies Ltd. This acquisition aims to enhance SciSparc's capabilities in the medical device market, particularly for treating gastroesophageal reflux disease (GERD) [1][4]. Company Overview - SciSparc Ltd. operates through its majority-owned subsidiary NeuroThera Labs Inc., focusing on clinical-stage pharmaceutical developments, particularly in cannabinoid pharmaceuticals [7]. - The company is engaged in drug development programs targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder (ASD) [7]. Acquisition Details - The acquisition includes the complete portfolio of intellectual property rights associated with the MUSE™ system, which is designed for transoral fundoplication, a minimally invasive procedure for GERD treatment [2][4]. - In exchange for the acquired assets, SciSparc will issue shares representing 19.99% of its outstanding share capital to Xylo upon closing of definitive agreements [4]. Market Potential - The global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to grow to $3.03 billion by 2030, with a compound annual growth rate (CAGR) of 3.24% from 2025 to 2030 [5]. - SciSparc plans to replicate Xylo's successful commercialization model from Greater China to high-growth regions such as North America, Europe, and Latin America through exclusive partnerships with regional distributors [3].

Core Viewpoint - SciSparc Ltd. has entered into a framework agreement for the mutual termination of its merger with AutoMax Motors Ltd., which includes repayment terms for outstanding loans [1][2]. Group 1: Termination of Merger - The parties have mutually agreed to terminate the Agreement and Plan of Merger dated April 10, 2024, making it null and void effective immediately [2]. Group 2: Loan Repayment Terms - AutoMax will repay a loan of $4.25 million with 9% annual interest in a lump-sum payment on January 1, 2028 [3]. - AutoMax will also repay a $2.0 million loan in monthly installments of $60,000 starting November 20, 2025, with 8% annual interest, and will pay accrued interest totaling $114,523 at the outset [4]. Group 3: Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders, including treatments for Tourette Syndrome, Alzheimer's disease, and autism spectrum disorder [5].

Core Insights - SciSparc Ltd. has filed a new international patent application in collaboration with Clearmind Medicine Inc. for a combination therapy targeting obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) [1][2][3] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes cannabinoid pharmaceuticals [4] - The company is currently developing drugs such as SCI-110 for Tourette Syndrome and SCI-210 for autism and status epilepticus [4] Industry Context - Obesity affects over 890 million people globally and is a significant risk factor for chronic conditions, while non-alcoholic fatty liver disease (NAFLD) impacts more than 30% of the adult population [2] - There is a limited number of treatment options available for these health challenges, highlighting the potential market opportunity for innovative therapies [2]

Group 1 - SciSparc Ltd. has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its ordinary shares maintained a minimum bid price of $1.00 per share for 10 consecutive business days [1][2] - The compliance determination by Nasdaq indicates that the prior bid price deficiency matter is now closed [2] - SciSparc is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes drug development programs for Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [3] Group 2 - The company is led by an experienced team of senior executives and scientists, emphasizing its expertise in cannabinoid pharmaceuticals [3] - SciSparc also has a controlling interest in a subsidiary that sells hemp seed oil-based products on the Amazon.com Marketplace [3]

Core Viewpoint - SciSparc Ltd. has announced the publication of a Japanese divisional patent for a novel pharmaceutical combination of paracetamol and palmitoylethanolamide (PEA), which may provide enhanced pain and fever relief with lower doses and fewer side effects compared to traditional paracetamol use [1][2]. Group 1: Patent and Innovation - The newly published patent introduces a combination of paracetamol and PEA that could lead to safer and more effective treatment options for millions globally [2]. - The combination aims to reduce the required dosage of paracetamol, thereby minimizing risks such as liver damage while improving outcomes for various types of pain and fever [3]. Group 2: Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes cannabinoid pharmaceuticals [4]. - The company is currently engaged in drug development programs targeting conditions such as Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [4].